Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
Abstract Background: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy const...
Gespeichert in:
| Veröffentlicht in: | Obesity Facts 2023-03, Vol.16 (2), p.149-163 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 163 |
|---|---|
| container_issue | 2 |
| container_start_page | 149 |
| container_title | Obesity Facts |
| container_volume | 16 |
| creator | Yazıcı, Dilek Yapıcı Eser, Hale Kıyıcı, Sinem Sancak, Seda Sezer, Havva Uygur, Melin Yumuk, Volkan |
| description | Abstract
Background: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems. Summary: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications. Key Messages: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA’s analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications. |
| doi_str_mv | 10.1159/000526808 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2900327935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A741498922</galeid><doaj_id>oai_doaj_org_article_730c193c9aeb41679ce4a9f6c809aca7</doaj_id><sourcerecordid>A741498922</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-2bf5f5c9bfb4a3e66ec77bcfd61670296c055517c8ad7147a973c2e1dceadd923</originalsourceid><addsrcrecordid>eNptks-L1DAUgIso7rp68C5S8KKHrvnRJs1JhsFdBwZGRE8eQvr60s1s23STjrD_vRlnHF2RHBJevnzvvfCy7CUll5RW6j0hpGKiJvWj7JwKwYqScP74dGbVWfYsxi0hgpaSPs3OuOClkrI-z74vezc6MH2-GiYDc-5tft3vwHR-LNbuFvPPOM2uxYLmXxDS2Yd8MZredzH3Yz7fYL70w9Qnx-z8GPeCTYPRzffPsyfW9BFfHPeL7NvVx6_LT8V6c71aLtYFVLWYC9bYylagGtuUhqMQCFI2YFtBhSRMCSBVVVEJtWllasAoyYEhbQFN2yrGL7LVwdt6s9VTcIMJ99obp38FfOi0CbODHrXkBKjioAw2ZdIrwNIoK6AmyoCRyfXh4Jp2zYApxTgH0z-QPrwZ3Y3u_A9NCWE1l_tq3h4Nwd_tMM56cBGw782Ifhc1k7wUlNeKJvTNP-jW70L63EQpQjiTileJujxQnUkduNH6lBjSanFw4Ee0LsUXsqSlqhXbV_Du8ACCjzGgPZVPid4PjD4NTGJf_93vifw9IX9qvDWhw3ACNleLg0JPrU3Uq_9Sxyw_AciXzy8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2900327935</pqid></control><display><type>article</type><title>Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Karger Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Yazıcı, Dilek ; Yapıcı Eser, Hale ; Kıyıcı, Sinem ; Sancak, Seda ; Sezer, Havva ; Uygur, Melin ; Yumuk, Volkan</creator><creatorcontrib>Yazıcı, Dilek ; Yapıcı Eser, Hale ; Kıyıcı, Sinem ; Sancak, Seda ; Sezer, Havva ; Uygur, Melin ; Yumuk, Volkan</creatorcontrib><description>Abstract
Background: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems. Summary: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications. Key Messages: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA’s analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications.</description><identifier>ISSN: 1662-4025</identifier><identifier>EISSN: 1662-4033</identifier><identifier>DOI: 10.1159/000526808</identifier><identifier>PMID: 36349778</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Antihypertensives ; Appetite depressants ; Body mass index ; Clinical trials ; Complications and side effects ; Diabetes ; Diabetes Mellitus, Type 2 - complications ; Disease prevention ; Dosage and administration ; Drug dosages ; Drug therapy ; Fatty acids ; Female ; GLP-1 receptor agonists ; Glucagon ; Glucagon-Like Peptide 1 ; Glucagon-Like Peptide-1 Receptor ; Glucose ; Health aspects ; Hemodynamics ; Humans ; Hypertension ; Hypoglycemic agents ; Hypoglycemic Agents - therapeutic use ; Insulin resistance ; Liver diseases ; Non-alcoholic Fatty Liver Disease - complications ; Obesity ; Obesity - complications ; Obesity - drug therapy ; Obesity - metabolism ; Overweight ; Oxidation ; Pathophysiology ; Peptides ; Review ; Review Article ; Weight control ; Weight Loss</subject><ispartof>Obesity Facts, 2023-03, Vol.16 (2), p.149-163</ispartof><rights>2022 The Author(s). Published by S. Karger AG, Basel</rights><rights>2022 The Author(s). Published by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2023 S. Karger AG</rights><rights>2022 The Author(s). Published by S. Karger AG, Basel . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at: https://uk.sagepub.com/en-gb/eur/reusing-open-access-and-sage-choice-content</rights><rights>Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-2bf5f5c9bfb4a3e66ec77bcfd61670296c055517c8ad7147a973c2e1dceadd923</citedby><cites>FETCH-LOGICAL-c586t-2bf5f5c9bfb4a3e66ec77bcfd61670296c055517c8ad7147a973c2e1dceadd923</cites><orcidid>0000-0001-6463-4916 ; 0000-0001-5603-0004 ; 0000-0002-6569-8142 ; 0000-0003-0072-5901</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028372/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028372/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,27614,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36349778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yazıcı, Dilek</creatorcontrib><creatorcontrib>Yapıcı Eser, Hale</creatorcontrib><creatorcontrib>Kıyıcı, Sinem</creatorcontrib><creatorcontrib>Sancak, Seda</creatorcontrib><creatorcontrib>Sezer, Havva</creatorcontrib><creatorcontrib>Uygur, Melin</creatorcontrib><creatorcontrib>Yumuk, Volkan</creatorcontrib><title>Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity</title><title>Obesity Facts</title><addtitle>Obes Facts</addtitle><description>Abstract
Background: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems. Summary: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications. Key Messages: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA’s analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications.</description><subject>Antihypertensives</subject><subject>Appetite depressants</subject><subject>Body mass index</subject><subject>Clinical trials</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Disease prevention</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Fatty acids</subject><subject>Female</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-Like Peptide 1</subject><subject>Glucagon-Like Peptide-1 Receptor</subject><subject>Glucose</subject><subject>Health aspects</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypoglycemic agents</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin resistance</subject><subject>Liver diseases</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Obesity - metabolism</subject><subject>Overweight</subject><subject>Oxidation</subject><subject>Pathophysiology</subject><subject>Peptides</subject><subject>Review</subject><subject>Review Article</subject><subject>Weight control</subject><subject>Weight Loss</subject><issn>1662-4025</issn><issn>1662-4033</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>DOA</sourceid><recordid>eNptks-L1DAUgIso7rp68C5S8KKHrvnRJs1JhsFdBwZGRE8eQvr60s1s23STjrD_vRlnHF2RHBJevnzvvfCy7CUll5RW6j0hpGKiJvWj7JwKwYqScP74dGbVWfYsxi0hgpaSPs3OuOClkrI-z74vezc6MH2-GiYDc-5tft3vwHR-LNbuFvPPOM2uxYLmXxDS2Yd8MZredzH3Yz7fYL70w9Qnx-z8GPeCTYPRzffPsyfW9BFfHPeL7NvVx6_LT8V6c71aLtYFVLWYC9bYylagGtuUhqMQCFI2YFtBhSRMCSBVVVEJtWllasAoyYEhbQFN2yrGL7LVwdt6s9VTcIMJ99obp38FfOi0CbODHrXkBKjioAw2ZdIrwNIoK6AmyoCRyfXh4Jp2zYApxTgH0z-QPrwZ3Y3u_A9NCWE1l_tq3h4Nwd_tMM56cBGw782Ifhc1k7wUlNeKJvTNP-jW70L63EQpQjiTileJujxQnUkduNH6lBjSanFw4Ee0LsUXsqSlqhXbV_Du8ACCjzGgPZVPid4PjD4NTGJf_93vifw9IX9qvDWhw3ACNleLg0JPrU3Uq_9Sxyw_AciXzy8</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Yazıcı, Dilek</creator><creator>Yapıcı Eser, Hale</creator><creator>Kıyıcı, Sinem</creator><creator>Sancak, Seda</creator><creator>Sezer, Havva</creator><creator>Uygur, Melin</creator><creator>Yumuk, Volkan</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7WY</scope><scope>7X7</scope><scope>7XB</scope><scope>883</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>M0F</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6463-4916</orcidid><orcidid>https://orcid.org/0000-0001-5603-0004</orcidid><orcidid>https://orcid.org/0000-0002-6569-8142</orcidid><orcidid>https://orcid.org/0000-0003-0072-5901</orcidid></search><sort><creationdate>20230301</creationdate><title>Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity</title><author>Yazıcı, Dilek ; Yapıcı Eser, Hale ; Kıyıcı, Sinem ; Sancak, Seda ; Sezer, Havva ; Uygur, Melin ; Yumuk, Volkan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-2bf5f5c9bfb4a3e66ec77bcfd61670296c055517c8ad7147a973c2e1dceadd923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antihypertensives</topic><topic>Appetite depressants</topic><topic>Body mass index</topic><topic>Clinical trials</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Disease prevention</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Fatty acids</topic><topic>Female</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-Like Peptide 1</topic><topic>Glucagon-Like Peptide-1 Receptor</topic><topic>Glucose</topic><topic>Health aspects</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypoglycemic agents</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin resistance</topic><topic>Liver diseases</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Obesity - metabolism</topic><topic>Overweight</topic><topic>Oxidation</topic><topic>Pathophysiology</topic><topic>Peptides</topic><topic>Review</topic><topic>Review Article</topic><topic>Weight control</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yazıcı, Dilek</creatorcontrib><creatorcontrib>Yapıcı Eser, Hale</creatorcontrib><creatorcontrib>Kıyıcı, Sinem</creatorcontrib><creatorcontrib>Sancak, Seda</creatorcontrib><creatorcontrib>Sezer, Havva</creatorcontrib><creatorcontrib>Uygur, Melin</creatorcontrib><creatorcontrib>Yumuk, Volkan</creatorcontrib><collection>Karger Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>ABI/INFORM Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade & Industry (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ABI/INFORM Trade & Industry</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Obesity Facts</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yazıcı, Dilek</au><au>Yapıcı Eser, Hale</au><au>Kıyıcı, Sinem</au><au>Sancak, Seda</au><au>Sezer, Havva</au><au>Uygur, Melin</au><au>Yumuk, Volkan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity</atitle><jtitle>Obesity Facts</jtitle><addtitle>Obes Facts</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>16</volume><issue>2</issue><spage>149</spage><epage>163</epage><pages>149-163</pages><issn>1662-4025</issn><eissn>1662-4033</eissn><abstract>Abstract
Background: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems. Summary: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress, and fibrosis also play a role in some of the complications. Key Messages: Treating obesity is not only enabling weight loss but ameliorating complications related to obesity. Thus, any antiobesity medication has to have some favorable effects on the complications. As far as the GLP-RA’s analogs are concerned, there seems to be an improvement in many of the complications regardless of the weight loss effect of these medications.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>36349778</pmid><doi>10.1159/000526808</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-6463-4916</orcidid><orcidid>https://orcid.org/0000-0001-5603-0004</orcidid><orcidid>https://orcid.org/0000-0002-6569-8142</orcidid><orcidid>https://orcid.org/0000-0003-0072-5901</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-4025 |
| ispartof | Obesity Facts, 2023-03, Vol.16 (2), p.149-163 |
| issn | 1662-4025 1662-4033 |
| language | eng |
| recordid | cdi_proquest_journals_2900327935 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Karger Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antihypertensives Appetite depressants Body mass index Clinical trials Complications and side effects Diabetes Diabetes Mellitus, Type 2 - complications Disease prevention Dosage and administration Drug dosages Drug therapy Fatty acids Female GLP-1 receptor agonists Glucagon Glucagon-Like Peptide 1 Glucagon-Like Peptide-1 Receptor Glucose Health aspects Hemodynamics Humans Hypertension Hypoglycemic agents Hypoglycemic Agents - therapeutic use Insulin resistance Liver diseases Non-alcoholic Fatty Liver Disease - complications Obesity Obesity - complications Obesity - drug therapy Obesity - metabolism Overweight Oxidation Pathophysiology Peptides Review Review Article Weight control Weight Loss |
| title | Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T23%3A29%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Impact%20of%20Glucagon-Like%20Peptide-1%20Receptor%20Analogs%20on%20the%20Complications%20of%20Obesity&rft.jtitle=Obesity%20Facts&rft.au=Yaz%C4%B1c%C4%B1,%20Dilek&rft.date=2023-03-01&rft.volume=16&rft.issue=2&rft.spage=149&rft.epage=163&rft.pages=149-163&rft.issn=1662-4025&rft.eissn=1662-4033&rft_id=info:doi/10.1159/000526808&rft_dat=%3Cgale_proqu%3EA741498922%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2900327935&rft_id=info:pmid/36349778&rft_galeid=A741498922&rft_doaj_id=oai_doaj_org_article_730c193c9aeb41679ce4a9f6c809aca7&rfr_iscdi=true |